FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: A report of five cases and review of the literature

Massimiliano Berretta, Fabrizio Di Benedetto, Alessandra Bearz, Cecilia Simonelli, Ferdinando Martellotta, Chiara Del Ben, Salvatore Berretta, Michele Spina, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

Colorectal cancers are rare in developing countries, but are the second most frequent malignancy in the affluent world. Data on colorectal cancer in HIV-positive patients are limited. Up to now, there are no published data on treatment patterns, response to therapy, or survival in this setting. Oxaliplatin is an antineoplastic agent currently indicated, concomitantly to fluorouracil and leucovorin, for the treatment of advanced colorectal cancer. The FOLFOX-4 regimen (oxaliplatin 85 mg/m2 as a two-hour infusion on day 1; leucovorin 200 mg/m2 as a two-hour infusion on days 1 and 2, fluorouracil as a bolus infusion on days 1 and 2, followed by a fluorouracil 22-hour infusion 600 mg/m2 for two consecutive days every two weeks), with concomitant highly active antiretroviral therapy (HAART) is feasible and active, while the HIV infection is not a limiting factor for its use. Moreover, the concomitant use of HAART does not seem to increase the toxicity of the FOLFOX-4 regimen.

Original languageEnglish
Pages (from-to)610-614
Number of pages5
JournalCancer Investigation
Volume26
Issue number6
DOIs
Publication statusPublished - Jul 2008

Keywords

  • Colorectal cancer
  • FOLFOX-4
  • HAART
  • HIV

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: A report of five cases and review of the literature'. Together they form a unique fingerprint.

  • Cite this